Results 21 to 30 of about 1,314 (191)

Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments [PDF]

Journal of Ophthalmic Inflammation and Infection
Background This study evaluates the long-term efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone ...
Ana Margarida Ferreira, Marta Inês Silva, Sónia Torres-Costa, Cláudia Oliveira-Ferreira, Ana Catarina Pedrosa, Luís Figueira, Joana Rodrigues Araújo   +6 more
doaj   +2 more sources

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®)

Journal of Ophthalmic Inflammation and Infection, 2020
Background The current article is a short review of an Alimera Sciences-sponsored symposium held during The 15th International Ocular Inflammation Society Congress in Taiwan on the 14th November 2019 entitled, ‘Preventing relapse of non-infectious ...
Bahram Bodaghi, Quan Dong Nguyen, Glenn Jaffe, Ramin Khoramnia, Carlos Pavesio   +4 more
doaj   +2 more sources

Ophthalmic corticosteroids-related adverse events: the FDA adverse event reporting system (FAERS) database pharmacovigilance study [PDF]

Frontiers in Pharmacology
BackgroundCorticosteroids are extensively used in ophthalmology, particularly for treating various inflammatory conditions. Despite their effectiveness, prolonged or high-dose corticosteroid use is associated with significant adverse drug reactions (ADRs)
Chengzhi Liu, Xinyu Wang, Xusheng Cao
doaj   +2 more sources

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience

Ophthalmology and Therapy, 2019
Introduction Diabetic macular oedema (DMO) remains a significant cause of sight loss in the UK. Despite macular laser and anti-VEGF agents, a large proportion of patients remain with persistent DMO.
James F. Young, Andrew Walkden, Amy Stone, Sajjad Mahmood   +3 more
doaj   +2 more sources

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

BMC Ophthalmology, 2018
Background To compare visual function and structural improvements in pseudophakic eyes with diabetic macular oedema (DMO) treated with the 0.19mg Fluocinolone Acetonide (FAc) intravitreal implant (IluvienTM) in a ‘real world’ setting.
William Fusi-Rubiano, Chandoshi Mukherjee, Mark Lane, Marie D. Tsaloumas, Nicholas Glover, Andrej Kidess, Alastair K. Denniston, Helen E. Palmer, Avinash Manna, Rupal Morjaria   +9 more
doaj   +2 more sources

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

BMC Health Services Research, 2019
Background Diabetic macular oedema (DMO) may lead to visual loss and blindness. Several pharmacological treatments are available on the National Health Service (NHS) to United Kingdom patients affected by this condition, including intravitreal vascular ...
Michal Pochopien, Annette Beiderbeck, Phil McEwan, Richard Zur, Mondher Toumi, Samuel Aballéa   +5 more
doaj   +2 more sources

Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema [PDF]

Drug Design, Development and Therapy, 2016
John Hall Medical Affairs, Alimera Sciences Ltd., Aldershot, Hampshire, UKI read “Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials” published in ...
Hall J
doaj   +3 more sources

The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience [PDF]

Journal of Ophthalmic Inflammation and Infection
Background The 0.19 mg fluocinolone acetonide (FAc) implant (ILUVIEN) has been approved for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Igor Kozak, Avinash Gurbaxani, Maya Pandova   +2 more
doaj   +2 more sources

Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series

BMJ Open Ophthalmology, 2020
Objective To assess the real-world effectiveness and safety of single injection of a fluocinolone acetonide (FAc) implant in previously treated patients with recurrent diabetic macular oedema (DMO) over a 36-month follow-up period.Methods and Analysis ...
Muna Ahmed, Christine Putri, Hibba Quhill, Fahd Quhill   +3 more
doaj   +2 more sources

Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations [PDF]

Journal of Ophthalmic Inflammation and Infection
Background Non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) is an inflammatory disease, which can significantly impair visual acuity if not adequately treated.
Uwe Pleyer, Carlos Pavesio, Elisabetta Miserocchi, Carsten Heinz, Helen Devonport, Víctor Llorenç, Tomás Burke, Vanda Nogueira, Laurent Kodjikian, Bahram Bodaghi   +9 more
doaj   +2 more sources